Google’s AI Revolutionizes Ad Creationby Lilu Anderson 12.02.2024Google expands generative AI features for advertisers in the U.S. and UK, allowing them to create ad campaigns more efficiently ...
Berachain NFT Frenzy: Next Crypto Gold Rush?by John Darbie 12.02.2024Over 1.7 million NFTs have been minted by airdrop hunters ahead of the launch of the highly anticipated blockchain project ...
Sovereign Wealth Funds Rally for Paris Agreement Goalsby Terry Bingman 12.02.2024Senior leaders from 21 sovereign wealth funds gathered to discuss investing in clean energy and achieving the goals of the ...
Barbey Heirs Push for VF Corp Board Shake-Upby Mark Eisenberg 12.02.2024Activist investor Engaged Capital receives support from VF Corp founding family as it seeks board seats and aims to bring ...
Dogecoin’s Price Potential: Breakout or Breakdown?by John Darbie 12.02.2024Dogecoin, the largest meme coin, could break out of its trading range with support at $0.075 and resistance at $0.088. ...
Bitcoin Boom: ETFs Ignite Frenzy, Experts Predict Surgeby John Darbie 12.02.2024Bitcoin's recent surge in price sparks investor interest, but caution prevails in the crypto market due to vulnerabilities and uncertainty ...
S&P 500 Rally Faces Emerging Risks: Sevens Research Reportby Mark Eisenberg 12.02.2024Sevens Research Report warns of potential risks ahead despite the S&P 500 rally and new all-time highs. Concerns include rate ...
FDA Clears T2 Biosystems’ Key Update in Sepsis Battleby Lilu Anderson 12.02.2024T2 Biosystems has received FDA clearance to update its T2Bacteria Panel, expanding its coverage of sepsis-causing pathogens and potentially leading ...
Bitcoin Wobbles, Immutable Soars Amid Crypto Shuffle: Market Updateby John Darbie 12.02.2024Bitcoin and Ethereum remain steady, with slight declines but still above key levels. Some cryptocurrencies gained traction while others faced ...
Gilead Acquires CymaBay: Liver Cure Leap?by Mark Eisenberg 12.02.2024Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...